Literature DB >> 9658137

Circumvention of immunity to the adenovirus major coat protein hexon.

S Roy1, P S Shirley, A McClelland, M Kaleko.   

Abstract

Immunity to adenoviruses is an important hurdle to be overcome for successful gene therapy. The presence of antibodies to the capsid proteins prevents efficacious adenovirus vector administration in vivo. We tested whether immunity to a particular serotype of adenovirus (Ad5) may be overcome with a vector that encodes the hexon sequences from a different adenovirus serotype (Ad12). We successfully constructed an adenovirus vector with a chimeric Ad5-Ad12 hexon which was not neutralized by plasma from C57BL/6 mice immunized with Ad5. The vector was also capable of transducing the livers of C57BL/6 mice previously immunized with Ad5.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9658137      PMCID: PMC109897     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  26 in total

1.  Immunology of gene therapy with adenoviral vectors in mouse skeletal muscle.

Authors:  Y Yang; S E Haecker; Q Su; J M Wilson
Journal:  Hum Mol Genet       Date:  1996-11       Impact factor: 6.150

Review 2.  The structural and functional diversity of Adenovirus capsid components.

Authors:  E Norrby
Journal:  J Gen Virol       Date:  1969-09       Impact factor: 3.891

3.  Phylogenetic relationships among adenovirus serotypes.

Authors:  A Bailey; V Mautner
Journal:  Virology       Date:  1994-12       Impact factor: 3.616

4.  Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression.

Authors:  Y Dai; E M Schwarz; D Gu; W W Zhang; N Sarvetnick; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

5.  Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice.

Authors:  T A Smith; M G Mehaffey; D B Kayda; J M Saunders; S Yei; B C Trapnell; A McClelland; M Kaleko
Journal:  Nat Genet       Date:  1993-12       Impact factor: 38.330

6.  Neutralization of adenoviruses: kinetics, stoichiometry, and mechanisms.

Authors:  C Wohlfart
Journal:  J Virol       Date:  1988-07       Impact factor: 5.103

7.  In vivo correction of low density lipoprotein receptor deficiency in the Watanabe heritable hyperlipidemic rabbit with recombinant adenoviruses.

Authors:  K F Kozarsky; D R McKinley; L L Austin; S E Raper; L D Stratford-Perricaudet; J M Wilson
Journal:  J Biol Chem       Date:  1994-05-06       Impact factor: 5.157

8.  Antigenic relationships among the 47 human adenoviruses determined in reference horse antisera.

Authors:  J C Hierholzer; Y O Stone; J R Broderson
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

9.  The refined crystal structure of hexon, the major coat protein of adenovirus type 2, at 2.9 A resolution.

Authors:  F K Athappilly; R Murali; J J Rux; Z Cai; R M Burnett
Journal:  J Mol Biol       Date:  1994-09-30       Impact factor: 5.469

10.  Three-dimensional structure of the adenovirus major coat protein hexon.

Authors:  M M Roberts; J L White; M G Grütter; R M Burnett
Journal:  Science       Date:  1986-05-30       Impact factor: 47.728

View more
  36 in total

Review 1.  The promise and potential hazards of adenovirus gene therapy.

Authors:  L S Young; V Mautner
Journal:  Gut       Date:  2001-05       Impact factor: 23.059

2.  Ovine adenovirus vectors overcome preexisting humoral immunity against human adenoviruses in vivo.

Authors:  C Hofmann; P Löser; G Cichon; W Arnold; G W Both; M Strauss
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

3.  Identification of the hexon region of an adenovirus involved in a new outbreak of keratoconjunctivitis.

Authors:  Y Imai; S Kameya; M Ohkoshi; K Yamaki; S Sakuragi
Journal:  J Clin Microbiol       Date:  2001-08       Impact factor: 5.948

4.  Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon.

Authors:  Hongju Wu; Igor Dmitriev; Elena Kashentseva; Toshiro Seki; Minghui Wang; David T Curiel
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

5.  Characterisation of hexon and fibre genes of a novel strain of adenovirus involved in epidemic keratoconjunctivitis.

Authors:  A K Adhikary; T Inada; J Numaga; E Suzuki; H Ushijima; U Banik; A Mukouyama; S Matsuno; N Okabe
Journal:  J Clin Pathol       Date:  2004-01       Impact factor: 3.411

Review 6.  Current strategies and future directions for eluding adenoviral vector immunity.

Authors:  Dinesh S Bangari; Suresh K Mittal
Journal:  Curr Gene Ther       Date:  2006-04       Impact factor: 4.391

7.  Structure-based identification of a major neutralizing site in an adenovirus hexon.

Authors:  Susan L Pichla-Gollon; Mark Drinker; Xiangyang Zhou; Feng Xue; John J Rux; Guang-Ping Gao; James M Wilson; Hildegund C J Ertl; Roger M Burnett; Jeffrey M Bergelson
Journal:  J Virol       Date:  2006-11-15       Impact factor: 5.103

Review 8.  Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business".

Authors:  Kimberly A Schoenly; David B Weiner
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

9.  Effect of preexisting immunity on an adenovirus vaccine vector: in vitro neutralization assays fail to predict inhibition by antiviral antibody in vivo.

Authors:  Susan L Pichla-Gollon; Shih-Wen Lin; Scott E Hensley; Marcio O Lasaro; Larissa Herkenhoff-Haut; Mark Drinker; Nia Tatsis; Guang-Ping Gao; James M Wilson; Hildegund C J Ertl; Jeffrey M Bergelson
Journal:  J Virol       Date:  2009-03-11       Impact factor: 5.103

10.  Identification of a suppressor mutation that improves the yields of hexon-modified adenovirus vectors.

Authors:  Joseph T Bruder; Ping Chen; Elena Semenova; Charlie A Thomas; Svetlana Konovalova; Greg Ekberg; Damodar Ettyreddy; Duncan McVey; Jason G Gall; C Richter King; Douglas E Brough
Journal:  J Virol       Date:  2013-07-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.